CellaVision: Overreaction on Temporary Corona-Related Challenges
Redeye cuts its EPS estimate for 2020 significantly due to the effect of the corona crisis, but keeps its 2021 estimate and remain positive to the case, arguing that yesterday’s stock price reaction was unjustified. However, our estimate changes lead us to lower our Base Case.